scholarly journals The Effect of Caffeine Intake and Passive Smoking on Umbilical Cord Blood Unit Quality Parameters

2019 ◽  
Vol 8 (S1) ◽  
Author(s):  
Amal Alasmari ◽  
Anadel Hakeem ◽  
Shahad Alsaigh ◽  
Amairah Aloushan ◽  
Emad Masuadi ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Passive Smoking ◽  
Quality Parameters ◽  
Caffeine Intake ◽  
Blood Unit ◽  
Cord Blood Unit

Enhanced engraftment of umbilical cord blood-derived stem cells in NOD/SCID mice by cotransplantation of a second unrelated cord blood unit

2005 ◽  
Vol 33 (10) ◽  
pp. 1249-1256 ◽  
Author(s):  
Alma J. Nauta ◽  
Alwine B. Kruisselbrink ◽  
Ellie Lurvink ◽  
Arend Mulder ◽  
Frans H. Claas ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Scid Mice ◽  
Blood Unit ◽  
Cord Blood Unit ◽  
Unrelated Cord Blood

Processing the 5-mL umbilical cord blood unit with the use of an automated wash procedure

Cytotherapy ◽  
2015 ◽  
Vol 17 (3) ◽  
pp. 336-337
Author(s):  
Anginette Batista ◽  
Deborah Lamontagne ◽  
Sauvai Chang-Fong ◽  
Kristin Rathmann ◽  
Joanne Sullivan ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Blood Unit ◽  
Cord Blood Unit

scholarly journals Identification and molecular characterization of Roseomonas genomospecies 5 isolated from Umbilical Cord Blood Unit

2017 ◽  
Vol 80 (1) ◽  
pp. 24-30
Author(s):  
J.M. Bello-López ◽  
I. Trejo-Uriostegui ◽  
C.A. Domínguez-Mendoza ◽  
C. Castañeda-García ◽  
J. Rojo-Medina
Keyword(s):  
Cord Blood ◽  
Molecular Characterization ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Blood Unit ◽  
Cord Blood Unit

Theoretical Availability of UCBT in High Body Weight Patients Who Received Haplo-SCT for High Risk Haematological Malignancies: Results of the Simulation of Search through BMDW According to International Guidelines

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3014-3014
Author(s):  
Maria Teresa Lupo Stanghellini ◽  
Annalisa Ruggeri ◽  
Jacopo Peccatori ◽  
Massimo Bernardi ◽  
Consuelo Corti ◽  
...  
Keyword(s):  
High Risk ◽  
Cord Blood ◽  
Myeloid Leukaemia ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Hematological Malignancies ◽  
Blood Unit ◽  
Cell Dose ◽  
Cord Blood Unit ◽  
Matched Donor

Abstract Background. Allogeneic transplantation of hematopoietic stem cells (allo-SCT) from an HLA-matched related or unrelated donor is a curative option for patients with high-risk hematological disease. In the absence of an HLA-matched donor, patients have been offered investigational transplant strategies involving alternative donors such as umbilical cord blood (UCB) or family haploidentical SCT (haplo-SCT). Through the years, the search for alternative donors has led the medical community to explore different strategies to provide every patient candidate to allo-SCT with a suitable donor. In patients lacking an HLA-matched donor in a due time, both UCB and family haploidentical donors are raising from investigational into frontline stem cell source for treatment of hematological malignancies. However, no prospective evaluation of the feasibility of these alternative sources is available and transplant centres usually apply an upfront choice between these two available options as the priority modality to offer an allo-SCT to each candidate patient. In our Institution, we adopted the policy to offer a family haplo-SCT to adult patients lacking an HLA-matched donor. Methods and results. Here we report results of the simulation of a systematic search of a cord blood unit for all the patients that, in the last 2 years, received in our Institution an haplo-SCT.Between January 2006 and July 2008, 62 patients received an haplo-SCT; median age was 53 y (0–20y 2; 21–40y 14; 41–50y 12; 51–60y 20; over 60y 14), median weight 66 kg. All patients were affected by high risk hematological malignancies (41 acute myeloid leukaemia, 9 acute lymphoid leukaemia, 4 myelodisplastic syndrome, 3 chronic myeloid leukaemia, 3 Hodgkin disease, 2 non Hodgkin disease), 23 in complete remission at transplant, 37 in persistence of disease, 3 received transplant as up-front treatment. All the patients received a myeloablative conditioning regimen based on fludarabine-treosulfan-ATG and the overall engraftment rate was 96%. In intention to treat (ITT) analysis all the patients requiring an allo-SCT received an haplo transplant. In our simulation, we searched on BMDW (www.bmdw.org) for an umbilical cord blood unit (UCB-U) according to criteria based on current available guidelines (Barker JN et al, Blood 2005; Gluckman E et al, Curr Opin Immunol, 2006; Brunstein C et al, Blood 2007; Tse W et al, Curr Opin Hematol, 2008). According to these standard criteria, patients and UCB units must be at least 4/6 HLA matched in A, B, and DR beta 1 (DRB1) loci with cell dose ≥3.0×107/kg total nucleated cell (TNC). Regarding the degree of HLA disparity, priority should be given for selecting UCB grafts in the following order: 6/6 > 5/6 > 4/6. If multiple UCB-U with the same level of HLA matching are available, the priority should be given to the UCB-U that are DRB1 matched with higher cell dose. The target cell dose can be reached by the selection of a single UCB unit or a double UCB units. In those patients for whom a second UCB unit could be identified, the second also should have a minimum of 4/6 antigens matched with the patient and with the first unit. For 6 out of 62 patients, we could find a single UCB unit, with median dose of TNC 5.25×107/kg and HLA matched 5/6 (5), 4/6 (1). For 56 patients a double UCB-U was available, with a median TNC dose of 4.90×107/kg and HLA matched 6/6+6/6 (2); 6/6+5/6 (3), 6/6+4/6 (1); 5/6+5/6 (17), 5/6+4/6 (17), 4/6+4/6 (16). Conclusions.: With the application of protocols of multiple units, UCB source is providing the chance of allogeneic SCT to all candidate patients otherwise receiving Haplo-SCT. A prospective comparison of Haplo versus cord in an ITT model, is warranted to identify the best alternative option in specific disease settings.

scholarly journals Optimization of the criteria for cord blood unit selection for transplantation in recipients of the different age groups: current view and prospects in Ukraine

2020 ◽  
Vol 8 (2) ◽  
Author(s):  
P. Nemtinov ◽  
◽  
A. Ustymenko ◽  
G. Lobyntseva ◽  
L. Panchenko ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Age Groups ◽  
Blood Bank ◽  
Unit Selection ◽  
Blood Unit ◽  
Cord Blood Bank ◽  
Cord Blood Unit ◽  
Selection For

Umbilical cord blood has been widely used to treat both malignant and non-malignant hematological diseases for over 30 years. During this time, more than 40,000 successful hematopoietic stem cell (HSC) transplantations of umbilical cord blood have been performed. However, today in Ukraine there is no public umbilical cord blood bank established for unrelated HSC transplantation to patients with oncohematological disorders (both children and adults). In this regard, the HSC units must be purchased abroad or the patients are sent to foreign clinics for high-cost treatment. The organization of a public umbilical cord blood bank in Ukraine would help in a short time to meet the needs of patients with oncohematological disorders for donor HSCs for unrelated transplantation and save significant funds for the treatment of patients abroad. According to the experience of the world's leading oncohematological centers, when it is impossible to find either a related or haploidentical donor or in all available registries – a unrelated transplant, the search continues in the registers of public cord blood banks and an umbilical cord blood unit that matches the criteria is usually found. The optimal choice of umbilical cord blood unit is crucial to maximize the likelihood of successful transplant engraftment and recipient survival after the transplantation, so the criteria for cord blood unit selection for unrelated transplantation are a bit broader than those used when matching donor-recipient pairs. The review presents the main criteria for cord blood unit selection according to the assessment of its quality, cell dose, HLA matching for unrelated transplantation to recipients of different age groups in accordance with international guidelines developed by the National Marrow Donor Program (NMDP), USA Center for International Blood and Brain Transplantation Research (CIBMTR), in collaboration with the NMDP Council Advisory Group, as well as in accordance with the American Society for Transplantation and Cellular Therapy (ASTCT) and the Seventh Edition of the NetCord-FACT International Standards for Cord Blood Collection, Banking, and Release for Administration.

Sign in / Sign up

Export Citation Format

Share Document